Novotech’s Post

Key opinion leaders (KOLs) interviewed by GlobalData highlight unmet needs in the kidney disease space, emphasizing the demand for next-generation therapies with alternate mechanisms of action. Ozempic, if approved, will be the first GLP-1 therapy option for patients with T2D and CKD. Learn more about how Ozempic can benefit CKD patients: #Healthcare #KidneyDisease #GlobalData #Ozempic #T2D #CKD

This study evaluates the impact of hemoperfusion (HP) on 28-day mortality in leptospirosis patients with renal failure and septic shock. #Hemoperfusion #Leptospirosis #RenalFailure #SepticShock

This study evaluates the impact of hemoperfusion (HP) on 28-day mortality in leptospirosis patients with renal failure and septic shock. #Hemoperfusion #Leptospirosis #RenalFailure #SepticShock

It’s #WorldKidneyDay! 🏥 To mark this global awareness date, we’ve compiled a highly granular dataset of End-Stage Renal Disease (ERSD). ℹ ESRD is the advanced stage of kidney disease requiring renal replacement therapy. Kidney transplantation offers improved outcomes but requires immunosuppressive treatment to prevent organ rejection. However, these medications pose risks such as #infections and #metabolic complications, highlighting the complexity of the condition. 📈 This dataset of over 800 patients was designed to help healthcare researchers better understand managing ERSD post-transplantation. 💡 Find out more on Health Data Research UK (HDR UK)’s Gateway: https://rb.gy/str27k #HealthData #EndStageRenalDisease #ESRD #PIONEERdataset #ResearchCollaboration #kidneydisease #Renal #DataScience #WorldKidneyDay #WorldKidneyDay2024 #Symptoms #Dialysis #PostTransplant #ChronicKidneyDisease#OPCS4 #SNOMED-CT #Imaging #Prescriptions #Outpatient 

We are delighted to introduce the Steroid PRO, the first validated patient-reported outcome #measure designed to assess the impact of glucocorticoid therapy on quality of life for people with #rheumatic diseases. Glucocorticoids are a cornerstone treatment for many autoimmune #rheumatic diseases. While highly effective, they can come with a range of side effects that can significantly impact patients' lives. A key challenge for both patients and health professionals, lies in balancing the benefits with potential side effects. Developed with extensive patient involvement, the Steroid PRO allows clinicians to effectively assess: Social impact, Impact on appearance, Psychological impact, and Treatment concerns. For permissions for use in clinical trials or practice, please visit the dedicated site: https://lnkd.in/exAZk7_a Susan Bridgewater Emma Dures Sarah Louise Mackie OXFORD UNIVERSITY INNOVATION LIMITED University of the West of England Anne-Marie Tetsche Sweeney

🚀 Happy to share that my first article for GlobalData Healthcare was published last week, discussing #GLP-1 therapies and their potential in treating Metabolic-Associated Steatohepatitis (#MASH). In this piece, I explore how these therapies, traditionally used for diabetes and obesity, are now emerging as promising treatments for MASH—a condition with, up until recently, no approved therapies. This development marks a significant step forward in addressing a growing global health challenge. Looking forward to writing more of these in the future, covering the metabolic disease space! Check out the full article here to learn more: GLP-1 Therapies: A New Frontier in MASH Treatment

#Kidneyfunctiontests industry is projected to witness a CAGR of 6.2% during the period 2023-2032. This growth can be attributed to surging awareness regarding availability of different diagnostic methods for kidney related disorders. #Kidneyfunction

In July 2019, Darren Ali was rushed to St. Paul's Hospital and diagnosed with the widow maker – the often-fatal type of heart attack. The cause was elevated levels of lipoprotein (a), or Lp (a), a condition that is almost entirely genetic where small, sticky particle that carries fats like cholesterol through the bloodstream. About 20% of Canadians have high levels of Lp(a), but most people don’t know it. Physicians and researchers at the St. Paul’s Hospital Healthy Heart Program are forming a registry to help identify more patients like Ali with elevated Lp(a), learn more about it, and connect patients to the right treatments. The database will be the first in the country for this specific disorder and will launch in April at St. Paul’s and Vancouver General Hospital, with plans to expand to Quebec and Ontario in the first year as well as other sites in the province. Learn more at: https://lnkd.in/gfsXDDEk #KnowLpa

#kidneydisease #eye #medicine #medicalsciences #healthcare https://lnkd.in/gzWRaYJx Abstract Background A better understanding of the association between chronic kidney disease (CKD) and #glaucoma is required to optimize clinical outcomes. Therefore, this study aimed to investigate the association of chronic kidney disease (CKD) with new diagnoses of glaucoma over time from January 2009 to December 2019. Method This retrospective propensity-matched cohort study utilizing Taiwanese electronic health records examined the incidence of newly diagnosed glaucoma in patients with and without chronic kidney disease (CKD). Conclusions Our cohort study spanning 12 years showed an elevated glaucoma risk following a CKD diagnosis compared to a frequency-matched non-CKD cohort. Our findings have relevance for the clinical practice of at-risk CKD patients.

#Exosome research is soaring with the potential to transform disease treatment. This boom is driven by the alarming rise in chronic disease, strides in exosome technology, and the increase in clinical studies targeting exosome-based research, according to BNN Breaking. We are providing the groundbreaking tools needed to advance #exosomeresearch with our ExoVerita Pro Platform. "With each breakthrough, we edge closer to a future where the management of chronic diseases is not just a vision, but a tangible reality, heralding a new dawn in medical science." - bnn Read the article> https://lnkd.in/gzTxpfKk #liquidbiopsy #precisionmedicine #healthcare